Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes invalidating and chronic postoperative morbidity, especially in patients with high stage disease. Theoretically, downstaging with neoadjuvant chemotherapy could shrink the tumour, making surgical treatment less extensive thereby diminishing the chance for morbidity.
Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes invalidating and chronic postoperative morbidity, especially in patients with high stage disease. Theoretically, downstaging with neoadjuvant chemotherapy could shrink the tumour, making surgical treatment less extensive, thereby diminishing the chance for morbidity.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
51
Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
NKI-AVL
Amsterdam, Netherlands
RECRUITINGtumour size change by neoadjuvant chemotherapy
tumour size change by neoadjuvant chemotherapy measured by RECIST 1.1
Time frame: 18 weeks
avoidance of exenterative or invalidating surgery
number of patients were surgery can be reduced after the neo-adjuvant chemotherapy
Time frame: 21 weeks
Chemotherapy related morbidity
Chemotherapy related morbidity measured by reported adverse events
Time frame: 21 weeks
overall survival
overall survival
Time frame: 5 years after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.